The global “Vasopressin For Vasoplegic Shock Market”, size is expected to gain momentum by reaching USD 2,657.9 million by 2027, while exhibiting a stellar CAGR of 14.8% between 2020 and 2027. This is attributable to the increasing prevalence of cardiovascular surgeries that propels the demand for vasopressin for vasoplegic shock across the globe. This information is published by Fortune Business Insights, in its latest report, titled, “Vasopressin for Vasoplegic Shock Market Size, Share & COVID-19 Impact Analysis, By Application (Sepsis, Post Cardiac Surgery, and Others) Regional Forecast, 2020-2027.” The report further mentions that the market stood at USD 890.9 million in 2019.
Get Request a Sample Copy of the Vasopressin for Vasoplegic Shock Report:
Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers and acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.
It offers figurative estimations for upcoming years on the basis of the recent developments and historic data. For gathering information and estimating revenue for all segments, researchers have used top-down and bottom-up approaches. On the basis of data collected from primary and secondary research and trusted data sources the report will help both existing and new aspirants for market to figure out and study the market’s needs, market size, and competition.
Major Vasopressin for Vasoplegic Shock Market Key players covered in the report include:
- Endo International plc (Dublin, Ireland)
- AMOMED Pharma (Vienna, Austria)
- La Jolla Pharmaceutical Company (California, U.S.)
- Pfizer Inc. (New York, U.S.)
- Ferring Vasopressin for Vasoplegic Shock (Saint-Prex, Switzerland)
- Fresenius Kabi Canada (Toronto, Canada)
- Astellas Pharma (Tokyo, Japan)
- Eagle Vasopressin for Vasoplegic Shock, Inc. (New Jersey, U.S.)
- Others
Vasopressin for Vasoplegic Shock Market Analysis 2021:
DRIVING FACTORS
Increasing Incidence of Cardiovascular Surgeries to Augment Growth
According to the Centers for Disease Control and Prevention (CDC), every year about 340,000 Coronary Artery Bypass Grafting (CABG) procedures are performed in the U.S. The increasing number of cardiovascular surgeries propels the demand for vasopressin to control the blood flow. Additionally, the growing number of CABG procedures and sepsis patients are boosting the demand for innovative vasopressin treatment options. This is expected to bode well for the global vasopressin for vasoplegic shock market growth during the forecast period.
SEGMENTATION
Post Cardiac Surgery Segment Held 25.2% in 2019
The post cardiac segment, based on application, held a market share of about 25.2% in 2019 and is likely to gain momentum owing to the increasing number of cardiac surgeries that require efficient post-cardiac treatment globally.
For more information visit :
https://www.fortunebusinessinsights.com/vasopressin-for-vasoplegic-shock-market-104065